GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xenon Pharmaceuticals Inc (NAS:XENE) » Definitions » Price-to-Tangible-Book

Xenon Pharmaceuticals (Xenon Pharmaceuticals) Price-to-Tangible-Book : 3.26 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xenon Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-26), Xenon Pharmaceuticals's share price is $40.10. Xenon Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $12.31. Hence, Xenon Pharmaceuticals's Price to Tangible Book Ratio of today is 3.26.

The historical rank and industry rank for Xenon Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

XENE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.42   Med: 3.13   Max: 4.38
Current: 3.26

During the past 13 years, Xenon Pharmaceuticals's highest Price to Tangible Book Ratio was 4.38. The lowest was 1.42. And the median was 3.13.

XENE's Price-to-Tangible-Book is ranked worse than
57.38% of 1220 companies
in the Biotechnology industry
Industry Median: 2.67 vs XENE: 3.26

A closely related ratio is called PB Ratio. As of today, Xenon Pharmaceuticals's share price is $40.10. Xenon Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $12.31. Hence, Xenon Pharmaceuticals's P/B Ratio of today is 3.26.


Xenon Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for Xenon Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xenon Pharmaceuticals Price-to-Tangible-Book Chart

Xenon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.38 3.29 2.97 3.42 3.74

Xenon Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 3.29 3.79 3.49 3.74

Competitive Comparison of Xenon Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, Xenon Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xenon Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Xenon Pharmaceuticals's Price-to-Tangible-Book falls into.



Xenon Pharmaceuticals Price-to-Tangible-Book Calculation

Xenon Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=40.10/12.311
=3.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Xenon Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Xenon Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Xenon Pharmaceuticals (Xenon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada.
Executives
Gary Patou director
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Justin D. Gover director SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Patrick Machado director 201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Steven Gannon director C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A0 V5G 4W8
Simon N. Pimstone director 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Ian Mortimer director, officer: PRESIDENT & CEO C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
Christopher John Kenney officer: Chief Medical Officer 200 - 3650 GILMORE WAY, BURNABY, A1 V5G 48W
Andrea Difabio officer: Chief Legal Officer BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Sherry Aulin officer: Chief Financial Officer 200 - 3650 GILMORE WAY, BURNABY A0 V5G 48W
Sherrington Robin officer: SVP Bus. & Corp. Development C/O XENON PHARMACEUTICALS INC., 200 - 3650 GILMORE WAY, BURNABY A1 V5G4W8
James R. Empfield officer: SVP, Drug Discovery 200 - 3650 GILMORE WAY, BURNABY A1 VG5 48W
Seggern Christopher Von officer: Chief Commercial Officer 200 - 3650 GILMORE WAY, BURNABY A1 V5G 48W